Posted from: Thursday, July 31, 2014 - 04:08 PM - Present

Vaniqa Patent Expiration

July 15, 2014 – The patent for Vaniqa (eflornithine hydrochloride) expires July 15.  Vaniqa is manufactured by SkinMedica.  Vaniqa is used in the treatment of hirutism.  When used in conjunction with any hair removal technique, Vaniqa works by reducing unwanted facial hair.  No generic alternatives have been released yet.

Adverse reactions or quality problems experienced with the use of a recalled product may be reported to the FDA’s MedWatch Adverse Event Reporting Program either online, by regular mail or by fax.


Actual drug patent expiration dates and availability of new medications are subject to change due to patent litigation, settlement agreements, additional patents, exclusivities, and final FDA approval.  Distribution and availability of new medications at pharmacies may not occur immediately following FDA approval.  Patients are advised to speak with their healthcare professional or pharmacist regarding appropriateness as well as actual availability.

*This is provided for information only.  The reference to any medication above does not mean the medication is covered by your plan.

Last Updated Wednesday, October 16, 2019 - 11:04 PM.